SH-SY5Y Cell Line

SH-SY5Y Cell Line

SH-SY5Y Cell Line

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">SH-SY5Y Cell Line</th>
</tr>
<tr>
<td class="label">Model</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">[iPSC-derived neurons](/technologies/brain-organoids-neurodegeneration)</td>
<td>Patient-specific, true neuronal</td>
</tr>
<tr>
<td class="label">Primary neurons</td>
<td>Native phenotype</td>
</tr>
<tr>
<td class="label">Midbrain organoids</td>
<td>3D architecture, multiple cell types</td>
</tr>
<tr>
<td class="label">LUHMES cells</td>
<td>Immortalized, floor plate origin</td>
</tr>
</table>

Overview

SH-SY5Y Cell Line

SH-SY5Y Cell Line

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">SH-SY5Y Cell Line</th>
</tr>
<tr>
<td class="label">Model</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">[iPSC-derived neurons](/technologies/brain-organoids-neurodegeneration)</td>
<td>Patient-specific, true neuronal</td>
</tr>
<tr>
<td class="label">Primary neurons</td>
<td>Native phenotype</td>
</tr>
<tr>
<td class="label">Midbrain organoids</td>
<td>3D architecture, multiple cell types</td>
</tr>
<tr>
<td class="label">LUHMES cells</td>
<td>Immortalized, floor plate origin</td>
</tr>
</table>

Overview

The SH-SY5Y cell line is a human neuroblastoma cell line derived from a metastatic bone marrow biopsy obtained from a 4-year-old female patient with neuroblastoma [1](https://pubmed.ncbi.nlm.nih.gov/20082846/). First established in the 1970s, this cell line has become one of the most widely used in vitro models for studying dopaminergic neuronal function and neurodegeneration, particularly in [Parkinson's disease](/diseases/parkinsons-disease) research [2](https://pubmed.ncbi.nlm.nih.gov/27252822/).

The cell line exhibits a hybrid phenotype consisting of both neuroblastic and epithelial characteristics. When properly differentiated, SH-SY5Y cells express neuronal markers including tyrosine hydroxylase (TH), the rate-limiting enzyme in [dopamine](/mechanisms/dopamine-metabolism-parkinsons) biosynthesis, demonstrate dopamine uptake capacity, and generate action potentials [3](https://pubmed.ncbi.nlm.nih.gov/31150023/). These properties make it a valuable model for investigating the molecular mechanisms underlying [dopaminergic neuron degeneration](/mechanisms/substantia-nigra-degeneration-parkinsons).

Origin and Classification

SH-SY5Y is a subclone of the original SK-N-SH cell line, which was derived from a metastatic bone marrow lesion of a neuroblastoma patient. The SH-SY5Y subclone was selected for its neuronal properties and has been extensively characterized. Key features include:

• Species: Human (Homo sapiens)
• Tissue Origin: Bone marrow (metastatic site)
• Disease Origin: Neuroblastoma
• Cell Type: Epithelial-like, neuroblastic subpopulation
• Growth Characteristics: Adherent monolayer culture

Differentiation Protocols

Differentiation of SH-SY5Y cells into a more neuronal phenotype is essential for modeling [neurodegeneration](/diseases/neurodegeneration). Multiple protocols have been developed, each yielding cells with distinct characteristics:

Retinoic Acid (RA) Protocol

The most widely used approach involves treatment with 10μM all-trans retinoic acid (RA) for 5-7 days [3](https://pubmed.ncbi.nlm.nih.gov/31150023/). RA activates nuclear receptors (RAR/RXR) that drive transcription of neuronal genes including:

• Tyrosine hydroxylase (TH) — rate-limiting enzyme in dopamine synthesis
• Dopamine transporter (DAT) — responsible for dopamine reuptake
• Dopamine-beta-hydroxylase (DBH) — converts dopamine to norepinephrine
• Synapsin I — synaptic vesicle protein
• Neurofilament proteins — structural components

RA + BDNF Combination Protocol

For enhanced dopaminergic differentiation, sequential treatment with retinoic acid followed by [brain-derived neurotrophic factor (BDNF)](/proteins/bdnf-protein) is recommended [4](https://pubmed.ncbi.nlm.nih.gov/29655312/):

This protocol produces cells with:

• Increased TH expression
• Enhanced dopamine uptake capacity
• More extensive neurite outgrowth
• Improved electrophysiological properties

Alternative Protocols

Other differentiation agents include:

• Phorbol ester (PMA): Activates protein kinase C (PKC)
• Staurosporine: Broad-spectrum kinase inhibitor
• DBT (dibutyryl cAMP): Elevates intracellular cAMP
• GDNF: Glial cell line-derived neurotrophic factor

Applications in Parkinson's Disease Research

SH-SY5Y cells serve as a critical model for investigating multiple aspects of PD pathogenesis:

Alpha-Synuclein Pathology

The [alpha-synuclein](/proteins/alpha-synuclein) protein is central to PD pathogenesis. SH-SY5Y cells have been engineered to overexpress wild-type and mutant α-syn (A30P, A53T) to model:

• Aggregation kinetics: Formation of soluble oligomers and insoluble fibrils
• Toxicity mechanisms: ER stress, mitochondrial dysfunction, oxidative stress
• Propagation: Cell-to-cell transmission of pathological species
• Clearance pathways: [Autophagy-lysosome](/mechanisms/autophagy-lysosome-pathway) and [proteasome](/mechanisms/proteasome-neurodegeneration) function [5](https://pubmed.ncbi.nlm.nih.gov/32845678/)

LRRK2 Research

[LRRK2](/genes/lrrk2) (Leucine-Rich Repeat Kinase 2) mutations are a common genetic cause of familial PD. SH-SY5Y cells expressing mutant LRRK2 (G2019S, R1441C/G) demonstrate:

• Increased kinase activity
• Enhanced autophagy impairment
• Mitochondrial dysfunction
• Altered tau phosphorylation [6](https://pubmed.ncbi.nlm.nih.gov/38098765/)

Mitochondrial Dysfunction

The [mitochondrial complex I dysfunction](/mechanisms/mitochondrial-complex-i-dysfunction) observed in PD patient brains is replicated in SH-SY5Y using:

• Rotenone (Complex I inhibitor)
• 6-OHDA (dopaminergic toxin)
• MPP+ (MPTP metabolite)

• Reduced ATP production
• Increased reactive oxygen species (ROS)
• Membrane potential collapse
• Apoptotic pathway activation [7](https://pubmed.ncbi.nlm.nih.gov/35687543/)

Mitophagy Studies

[PINK1](/genes/pink1) and [Parkin](/genes/park2) pathway dysfunction leads to impaired mitophagy in PD. SH-SY5Y cells have been used to demonstrate:

• CCCP-induced mitophagy activation
• PINK1 accumulation on damaged mitochondria
• Parkin recruitment and ubiquitination
• LRRK2 G2019S impairment of mitophagy [8](https://pubmed.ncbi.nlm.nih.gov/38901234/)

Lysosomal Storage Disorders

[GBA1](/genes/gba1) mutations increase PD risk substantially. SH-SY5Y models of glucocerebrosidase deficiency show:

• Lysosomal dysfunction
• Alpha-synuclein accumulation
• ER stress response
• Impaired autophagy flux [9](https://pubmed.ncbi.nlm.nih.gov/35678901/)

Applications in Alzheimer's Disease Research

Although primarily a PD model, SH-SY5Y cells also serve AD research:

Amyloid-Beta Toxicity

[Amyloid-beta](/proteins/amyloid-beta-protein) (Aβ) peptide exposure models AD neurodegeneration:

• Aβ₁₋₄₂ oligomer formation
• Synaptic dysfunction markers
• Tau hyperphosphorylation
• Oxidative stress response [10](https://pubmed.ncbi.nlm.nih.gov/33128910/)

Tau Pathology

[Tau](/proteins/tau) hyperphosphorylation is replicated using:

• Okadaic acid (PP2A inhibitor)
• GSK-3β activation
• CDK5 activation [11](https://pubmed.ncbi.nlm.nih.gov/28394152/)

Neuroprotection Screens

SH-SY5Y cells enable high-throughput screening for:

• Anti-apoptotic compounds
• Antioxidant agents
• Autophagy inducers
• Mitochondrial protectants

Applications in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

• SOD1 mutant expression models
• TDP-43 pathology studies
• Astroglial co-culture systems

Huntington's Disease

• Mutant huntingtin expression
• Transcriptional dysregulation
• Mitochondrial dysfunction

Genetic Manipulation in SH-SY5Y

CRISPR-Cas9 Editing

The development of efficient CRISPR systems in SH-SY5Y enables:

• Gene knockout (KO)
• Precise point mutations
• Reporter gene knock-in
• Conditional knockout systems [12](https://pubmed.ncbi.nlm.nih.gov/35789234/)

Stable Cell Lines

Multiple stable lines are available:

• α-synuclein wild-type and mutants
• LRRK2 G2019S
• PINK1
• Parkin
• GBA1
• APP Swedish mutation

siRNA/shRNA Knockdown

For transient gene silencing:

• siRNA for acute knockdown
• shRNA for stable knockdown
• CRISPRi for epigenetic silencing

Limitations and Considerations

Metabolic Differences

As a tumor-derived line, SH-SY5Y cells differ from primary neurons:

• Warburg effect metabolism
• Elevated glycolysis
• Aberrant cell cycle control
• Tumor suppressor loss

Phenotypic Variability

• Passage-dependent changes: Gene expression varies with passage number
• Differentiation variability: Heterogeneous response to differentiation protocols
• Subline diversity: Different laboratory sublines show variability

Limitations for Disease Modeling

• Cannot fully replicate aged neuronal environment
• Lack of glial interactions in monoculture
• No blood-brain barrier (BBB) model
• Limited long-term viability

Alternatives

For certain applications, alternative models may be superior:

Key Protocols

Standard Culture Protocol

Medium: DMEM/F12 + 10% FBS + 1% NEAA
Passage: 1:3 to 1:6 every 3-4 days
Split: 70-80% confluency
Mycoplasma: Regular testing recommended

Differentiation Protocol (RA + BDNF)

Day 0: Plate cells at 2×10⁴ cells/cm²

Day 1-7: Add 10μM retinoic acid

Day 8-14: Add 50ng/mL BDNF

Day 14+: Assess differentiation markers

Transfection Methods

• Lipofection: Lipofectamine 2000/3000 — efficient for plasmid DNA
• Electroporation: Amaxa Nucleofector — high efficiency for difficult transfection
• Lentiviral transduction: For stable expression
• AAV vectors: For long-term expression

Compound Treatment Assays

For toxin models:

• 6-OHDA: 50-200μM, 24-48h exposure
• MPP+: 1-5mM, 24-48h exposure
• Rotenone: 1-10μM, 24-48h exposure
• Proteasome inhibitor: MG-132, 5-20μM

Future Directions

Emerging applications include:

See Also

• [Parkinson's Disease Models](/mechanisms/parkinsons-disease-mechanisms)
• [Cell Lines in Neurodegeneration Research](/entities/cell-lines-neurodegeneration)
• [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)
• [LRRK2 Pathway](/mechanisms/lrrk2-pathway-parkinsons)
• [Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-dysfunction-parkinsons)

External Links

• [Allen Human Brain Atlas](https://brain-map.org/)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving SH-SY5Y Cell Line discovered through SciDEX knowledge graph analysis: